ACOG: Alpha Cognition Inc. Kelajakdagi narxning foydaga nisbati
Alpha Cognition (ACOG) kompaniyasida miya patologiyalari uchun dori ishlab chiqish patent himoyasi va qat'iy tartibga soluvchi nazoratga tayanadi, bu esa generik alternativlarning kengayishini cheklaydi. Ushbu narxlar grafigi joriy P/E koeffitsiyenti 0.00 ekanligini tasdiqlaydi. Biznes hozirda o'zining asosiy Altsgeymer kasalligini davolash vositasini tijoratlashtirish bosqichiga o'tmoqda, ammo yagona mahsulotga yuqori bog'liqlik sotuvlar boshlanishida sezilarli bozor risklarini yuzaga keltiradi.
Alpha Cognition Corp (ACOG) moliyaviy va bozor koʻrsatkichlari kesimi
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- balans bo'yicha xususiy kapital ma'lumotlari:
- kompaniyaning jami qarzi va likvidligi ko'rsatkichlari:
Umumiy qarzning xususiy kapitalga nisbati Alpha Cognition|ACOG - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Qisqa muddatli qarzning kapitalga nisbati Alpha Cognition|ACOG - Kompaniyaning umumiy qarzi|Qarzning balans kapitallashuviga nisbati Alpha Cognition Inc|ACOG - Uzoq muddatli qarz|Kompaniyaning qisqa muddatli qarzlari Alpha Cognition|Tezkor likvidlik alphacognition.com
- foyda va bozor koeffitsiyentlari statistikasi:
ACOG - Kompaniya foydasi|Prognoz qilingan kelajakdagi foyda Alpha Cognition|ACOG - Biznesning o‘zini qoplash muddati|Prognoz qilingan narxning foydaga nisbati Alpha Cognition|ACOG - Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|EV/EBITDA multiplikatori Alpha Cognition Inc|ACOG - Amortizatsiya chegirilmasdan oldingi operatsion daromad|So'nggi o'n ikki oy davomida bir aksiya uchun foyda Alpha Cognition|ACOG - So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda|So'nggi o'n ikki oy davomida bir aksiya uchun foydaning yillik o'sishi alphacognition.com|ACOG - Bu yil bir aksiya uchun foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi Alpha Cognition
Kompaniyaning fundamental tahlili:ACOG Alpha Cognition Inc.
Alpha Cognition global nevrologiya bozori uchun Altsgeymer kasalligining innovatsion davolash usullarini ishlab chiqmoqda. Forward P/E ko'rsatkichi joriy aksiya narxining kelajakdagi davr uchun prognoz qilingan foydaga nisbati sifatida hisoblanadi. Ushbu ko'paytiruvchi biznesning kengayish sur'atlari va yangi dori vositalarining samaradorligiga oid bozor kutganlarini o'lchaydi. Yuqori premium investorlarning o'sishga bo'lgan ishonchini tasdiqlaydi, ammo korreksiya xavfini oshiradi. Alpha Cognition kompaniyasining forward P/E baholash dinamikasini tahlil qilish orqali strateg uning kapitalizatsiyasining barqarorligini aniqlaydi.
Alpha Cognition (ACOG) raqobatchilari
Kelajakdagi narxning foydaga nisbati Biogen (BIIB)|Kelajakdagi narxning foydaga nisbati NBIX (Neurocrine)|Kelajakdagi narxning foydaga nisbati Regencell RGC|AXSM (Axsome Corp) - Narxning kutilayotgan foydaga nisbati|ACADIA Pharmaceuticals - Forvard P/E multiplikatori|Kelajakdagi narx-foyda multiplikatori XENE (xenon-pharma.com)|VKTX: Forvard P/E multiplikatori|Supernus Pharmaceuticals, Inc. (SUPN) - Forvard P/E multiplikatori|Prognoz qilingan narxning foydaga nisbati CPRX|DNLI: Kelajakdagi narx-foyda multiplikatori|Forvard P/E multiplikatori HRMY|Prognoz qilingan narxning foydaga nisbati biohavenpharma.com BHVN|Kelajakdagi narxning foydaga nisbati Amylyx Pharmaceuticals, Inc. AMLX|Trevi Therapeutics Inc (TRVI) - Prognoz qilingan narx-foyda nisbati|Praxis Medicines - Forvard P/E multiplikatori|Forvard narx-foyda multiplikatori Anavex Life Sciences Corp (AVXL)|CeriBell, Inc. (CBLL) - Kelajakdagi narxning foydaga nisbati|Narxning kelajakdagi foydaga nisbati PRTA|ALEC (Alector Inc.) - Forvard P/E multiplikatori|Annexon Biosciences (ANNX) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Prognoz qilingan narxning foydaga nisbati OMER (Omeros Corporation)|Kapitalizatsiyaning kelajakdagi foydaga nisbati NGNE|Forvard P/E multiplikatori ACIU (AC Immune)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati voyagertherapeutics.com (VYGR)|NMRA - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati Scilex Holding|Tevogen Bio Holdings, Inc. (TVGN) - Kelajakdagi narxning foydaga nisbati|Narxning kelajakdagi foydaga nisbati CGTX|IKT (Inhibikase Therapeutics) - Forvard P/E multiplikatori|Forvard P/E multiplikatori cassavasciences.com|Forvard P/E multiplikatori ASRT|Prognoz qilingan narxning foydaga nisbati coyatherapeutics.com COYA|Kelajakdagi narxning foydaga nisbati Vistagen VTGN|Ovid Therapeutics Inc (OVID) - Prognoz qilingan narx-foyda nisbati|Acumen Pharmaceuticals - Forvard P/E multiplikatori|Forvard narx-foyda multiplikatori cervomed.com (CRVO)|alteritytherapeutics.com (ATHE) - Kelajakdagi narxning foydaga nisbati|Narxning kelajakdagi foydaga nisbati CLNN|PEPG (PepGen Inc) - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Jupiter Neurosciences, Inc. JUNS|Prognoz qilingan narxning foydaga nisbati RLMD (Relmada Therapeutics)|Forvard P/E multiplikatori annovisbio.com (ANVS)|Kelajakdagi narxning foydaga nisbati Grace Therapeutics GRCE|Kelajakdagi narx-foyda multiplikatori AIFF|KLTO - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati NeuroSense Therapeutics|RVPH: Forvard P/E multiplikatori|MetaVia (MTVA) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati NeurAxis|Kelajakdagi narxning foydaga nisbati HSDT|Kelajakdagi narxning foydaga nisbati Passage Bio, Inc. (PASG)|NEUP: Narxning kutilayotgan foydaga nisbati|Forvard P/E multiplikatori NERV (Minerva Neurosciences)|Kelajakdagi narx-foyda multiplikatori ATHA|Addex Therapeutics Ltd - Forvard P/E multiplikatori|ALZN - Forvard P/E multiplikatori|CYCN (cyclerion.com) - Prognoz qilingan narxning foydaga nisbati|Protagenic Therapeutics, Inc. - Kelajakdagi narx-foyda multiplikatori|KTTA (Pasithea Therapeutics Corp) - Forvard P/E multiplikatori|Prognoz qilingan narxning foydaga nisbati Cortigent Medical (CRGT)|Kelajakdagi narxning foydaga nisbati Avenue Therapeutics, Inc. (ATXI)|BCLI - Prognoz qilingan narx-foyda nisbati|Forvard P/E multiplikatori CARA (Cara Therapeutics, Inc)|Forvard narx-foyda multiplikatori Chromocell|ELYM - Kelajakdagi narxning foydaga nisbati|ITCI (Intra-Cellular Therapies) - Narxning kelajakdagi foydaga nisbati|LBPH: Forvard P/E multiplikatori|MRNS - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Prognoz qilingan narxning foydaga nisbati NKGN|NRBO (NeuroBo Pharma) - Kapitalizatsiyaning kelajakdagi foydaga nisbati|Forvard P/E multiplikatori SAGE|Kapitalizatsiyaning prognoz qilingan foydaga nisbati synaptogen.com|Kelajakdagi narxning foydaga nisbati Trevena TRVN|Vigil Neuroscience Inc. (VIGL) - Prognoz qilingan narx-foyda nisbati|WENA - Kelajakdagi narxning foydaga nisbati|CERE (Cerevel Corp) - Narxning kelajakdagi foydaga nisbati
